{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:39:12Z","timestamp":1790404752808,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.wneu.2019.09.158","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T19:33:20Z","timestamp":1570649600000},"page":"215-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4101-9325","authenticated-orcid":false,"given":"Eduardo","family":"Cambruzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2019.09.158_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/bjh.15661","article-title":"Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma","volume":"184","author":"Fox","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.wneu.2019.09.158_bib2","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.09.158_bib3","first-page":"12971303","article-title":"Primary CNS lymphoma at the first relapse\/progression: characteristics, management, and outcome of 256 patients from the French LOC network","volume":"18","author":"Langner-Lemervier","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib4","first-page":"261","article-title":"Primary intracerebral malignant lymphoma: report of 248 cases","volume":"92","author":"Bataille","year":"2000","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2019.09.158_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.09.158_bib6","first-page":"5505","article-title":"Immunohistochemical profile and prognostic significance in primary central nervous system lymphoma: analysis of 89 cases","volume":"14","author":"Liu","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.wneu.2019.09.158_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3960\/jslrt.17029","article-title":"Clinicopathological analysis of 320 cases of diffuse large B-cell lymphoma using the Hans classifier","volume":"57","author":"Ichiki","year":"2017","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.wneu.2019.09.158_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/ejh.12763","article-title":"Central nervous system prophylaxis in diffuse large B-cell lymphoma","volume":"97","author":"Zahid","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.wneu.2019.09.158_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hon.2375","article-title":"PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival","volume":"35","author":"Four","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib10","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.10851","article-title":"The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis","volume":"95","author":"Olson","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.wneu.2019.09.158_bib11","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-002-0498-8","article-title":"Primary central nervous system (CNS) lymphoma in immunocompetent patients","volume":"81","author":"Plasswilm","year":"2002","journal-title":"Ann Hematol"},{"key":"10.1016\/j.wneu.2019.09.158_bib12","first-page":"1068","article-title":"Primary central nervous system lymphoma in immunocompetent individuals: a single center experience","volume":"6","author":"Aki","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.wneu.2019.09.158_bib13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jocn.2018.08.022","article-title":"An unusual presentation of cerebellar lymphoma","volume":"57","author":"Harley","year":"2018","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2019.09.158_bib14","doi-asserted-by":"crossref","first-page":"16822","DOI":"10.18632\/oncotarget.24706","article-title":"Prognostic value of early 18F-FDG PET scanning evaluation in immunocompetent primary CNS lymphoma patients","volume":"9","author":"Birsen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.wneu.2019.09.158_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.09.158_bib16","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomization of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.wneu.2019.09.158_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1023\/A:1012946812930","article-title":"Homozygous deletion of INK4a\/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type","volume":"55","author":"Hayashi","year":"2001","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4103\/2278-330X.221341","article-title":"Primary central nervous system lymphoma in immunocompetent patients: a regional cancer center experience","volume":"6","author":"Rudresha","year":"2017","journal-title":"South Asia J Cancer"},{"key":"10.1016\/j.wneu.2019.09.158_bib19","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2006.03.012","article-title":"CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course","volume":"247","author":"Ekstein","year":"2006","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.wneu.2019.09.158_bib21","doi-asserted-by":"crossref","first-page":"478","DOI":"10.4103\/ijmpo.ijmpo_202_16","article-title":"Clinicopathological features and outcomes in primary central nervous system lymphoma: a 10-year experience","volume":"38","author":"Puligundla","year":"2017","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib22","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/neup.12276","article-title":"Primary central nervous system lymphomas and related diseases: pathological characteristics and discussion of the differential diagnosis","volume":"36","author":"Sugita","year":"2016","journal-title":"Neuropathology"},{"key":"10.1016\/j.wneu.2019.09.158_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2012.05.021","article-title":"Central nervous system lymphoma in immunocompetent patients: The North Shore-Long Island Jewish Health System Experience","volume":"20","author":"Zhang","year":"2013","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.wneu.2019.09.158_bib24","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4103\/0971-5916.187109","article-title":"A\u00a0clinicopathological study of primary central nervous system lymphoma & their associations with Epstein-Barr virus","volume":"143","author":"Sharma","year":"2016","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.wneu.2019.09.158_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/his.12706","article-title":"Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart","volume":"67","author":"Chang","year":"2015","journal-title":"Histopathology"},{"key":"10.1016\/j.wneu.2019.09.158_bib26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/NEN.0000000000000076","article-title":"CNS lymphoma: a practical diagnostic approach","volume":"73","author":"Giannini","year":"2014","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"key":"10.1016\/j.wneu.2019.09.158_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3109\/00313025.2010.508786","article-title":"Primary central nervous system lymphoma: a clinicopathological study of 75 cases","volume":"42","author":"Preusser","year":"2010","journal-title":"Pathology"},{"key":"10.1016\/j.wneu.2019.09.158_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/neuonc\/not012","article-title":"Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma","volume":"15","author":"He","year":"2013","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/modpathol.2009.164","article-title":"Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the non germinal center subtype: a retrospective analysis of 31 cases","volume":"23","author":"Hattab","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.wneu.2019.09.158_bib30","series-title":"WHO Classification of Haematopoietic and Lymphoid Tissues","first-page":"300","article-title":"Diffuse large B-cell lymphoma","author":"Kluin","year":"2017"},{"key":"10.1016\/j.wneu.2019.09.158_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.wneu.2019.09.158_bib32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3892\/mco.2013.110","article-title":"Clinical presentation of anaplastic large-cell lymphoma in the central nervous system","volume":"1","author":"Nomura","year":"2013","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11060-011-0555-z","article-title":"Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma","volume":"104","author":"Song","year":"2011","journal-title":"Neurooncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1789.2009.01074.x","article-title":"Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance","volume":"30","author":"Raoux","year":"2010","journal-title":"Neuropathology"},{"key":"10.1016\/j.wneu.2019.09.158_bib35","first-page":"17","article-title":"Primary central nervous system lymphoma \u2013 part 1: epidemiology, diagnosis, staging, and prognosis","volume":"32","author":"Lukas","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.wneu.2019.09.158_bib36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-013-1169-7","article-title":"Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC (low) BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B-cell lymphomas","volume":"126","author":"Brunn","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2019.09.158_bib37","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.4049\/jimmunol.1402341","article-title":"Primary central nervous system (CNS) lymphoma B-cell receptors recognize CNS proteins","volume":"195","author":"Montesinos-Rongen","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.wneu.2019.09.158_bib38","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2019.09.158_bib39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/path.2399","article-title":"Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways","volume":"216","author":"Booman","year":"2008","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.wneu.2019.09.158_bib40","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1093\/annonc\/mdr436","article-title":"Clinical relevance of flow citometria imuno phenotypic of the cerebrospinal fluid in patients with diffuse large B-cell lymphoma","volume":"23","author":"Alvarez","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib41","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/ijc.25236","article-title":"Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant C cells","volume":"127","author":"Venetz","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.wneu.2019.09.158_bib42","first-page":"e11","article-title":"Primary central nervous system lymphoma \u2013 part 2: modern therapeutic management and future directions","volume":"32","author":"Lukas","year":"2018","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.wneu.2019.09.158_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1182\/blood.2019000633","article-title":"R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-\u03b1 in primary CNS lymphoma","volume":"134","author":"Ferreri","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.09.158_bib44","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/leu.2011.165","article-title":"Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas","volume":"25","author":"Nowakowski","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.wneu.2019.09.158_bib45","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2015-03-632430","article-title":"Frontline rituximab, cyclophosphamid docorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBC","volume":"126","author":"Offner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.wneu.2019.09.158_bib46","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11060-009-0032-0","article-title":"Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status","volume":"97","author":"Kurzwelly","year":"2010","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2019.09.158_bib47","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.wneu.2019.09.158_bib48","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00381-018-3765-2","article-title":"Medulloblastoma, WNT-activated\/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation","volume":"34","author":"Cambruzzi","year":"2018","journal-title":"Childs Nerv Syst"},{"key":"10.1016\/j.wneu.2019.09.158_bib49","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/WCO.0000000000000490","article-title":"The 2016 WHO classification of central nervous system tumors: what neurologists need to know","volume":"30","author":"DeWitt","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.wneu.2019.09.158_bib50","author":"Otani"},{"key":"10.1016\/j.wneu.2019.09.158_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/neuros\/nyy096","article-title":"Craniotomy and survival for primary central nervous system lymphoma","volume":"84","author":"Rae","year":"2019","journal-title":"Neurosurgery"},{"key":"10.1016\/j.wneu.2019.09.158_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMc1704610","article-title":"Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma","volume":"377","author":"Abranson","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2019.09.158_bib53","doi-asserted-by":"crossref","first-page":"e1626653","DOI":"10.1080\/2162402X.2019.1626653","article-title":"High tumoral PD-L1 expression and low PD-1+ or CD8+ tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system","volume":"8","author":"Kim","year":"2019","journal-title":"Oncoimmunology"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019326026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875019326026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:47:18Z","timestamp":1761814038000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875019326026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":53,"alternative-id":["S1878875019326026"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2019.09.158","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary Intra-Axial Diffuse Large B-Cell Lymphoma in Immunocompetent Patients: Clinical Impact of Molecular Analysis and Histogenetic Evaluation","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2019.09.158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}